![Sang-Woo Lee](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sang-Woo Lee
Director/Miembro de la Junta en Geneos Therapeutics, Inc. .
Cargos activos de Sang-Woo Lee
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Korea Investment Partners Co., Ltd.
![]() Korea Investment Partners Co., Ltd. Investment ManagersFinance Korea Investment Partners Co., Ltd(Korea Investment Partners). is a Private Equity/Venture Capital firm, a subsidiary of Korea Investment Holdings Co., Ltd. founded in 1986. Korea Investment Partners Co., Ltd. is headquartered in Seoul. | Inversor de Capital Privado | 14/04/2014 | - |
Geneos Therapeutics, Inc.
![]() Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Director/Miembro de la Junta | 03/03/2021 | - |
Historial de carrera de Sang-Woo Lee
Estadísticas
Internacional
Corea del Sur | 2 |
Estados Unidos | 2 |
Operativa
Private Equity Investor | 1 |
Director/Board Member | 1 |
Sectorial
Finance | 2 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Korea Investment Partners Co., Ltd.
![]() Korea Investment Partners Co., Ltd. Investment ManagersFinance Korea Investment Partners Co., Ltd(Korea Investment Partners). is a Private Equity/Venture Capital firm, a subsidiary of Korea Investment Holdings Co., Ltd. founded in 1986. Korea Investment Partners Co., Ltd. is headquartered in Seoul. | Finance |
Geneos Therapeutics, Inc.
![]() Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Sang-Woo Lee
- Experiencia